CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.

NEXT STORY
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
PREV STORY
Bioethanol Yeast Market Size, Share & Trends Analysis Report By Product Type, By Application, By Region And Segment Forecasts, 2021 – 2028
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chembio Diagnostics Reports 2016 Financial Results

MEDFORD, N.Y., March 07, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader ...

author_avatar
NASDAQ Market News

Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update

- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b ...

author_avatar
NASDAQ Market News

Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices

TUSTIN, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a ...

author_avatar
NASDAQ Market News